2786 results about "Protide" patented technology

The invention discloses a small CRISPR (clustered regularly interspaced short palindromic repeats)-Cas gene editing system and application thereof. According to the invention, based on microbial genome and metagenome data, a class of CRISPR-Cas family protein is mined through a biological information method, and is named as Cas12r. A CRISPR-Cas12r editing tool constructed on the basis of the gene can realize gene editing in prokaryotic or eukaryotic cells. The CRISPR-Cas12r gene editing system obtained by the invention has the characteristics of miniaturization and various PAM types.

This invention discloses a milk protein containing composition comprising: at least one milk protein; at least a first protein; at least a second protein; and at least a linker comprising an amino acid sequence coded by nucleotide sequence which is at least 80% similar to sequences selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21

The invention discloses three pattern recognition protein Hc beta GRP genes for preventing and treating fall webworms, dsRNA and application thereof. Specifically, the nucleotide sequences of the three pattern recognition protein Hc beta GRP genes for preventing and treating fall webworms are respectively SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3. The recombinant Hc beta GRP protein is successfully obtained through a prokaryotic expression system, an in-vitro bacteriostatic test proves that the recombinant Hc beta GRP protein, the Hc beta GRP protein and the dsRNA have direct bacteriostatic activity, dsRNA is designed based on a pattern recognition protein Hc beta GRP gene, a hyphantria cunea Hc beta GRP dsRNA interference system implemented by using an injection method is established, an obvious gene silencing effect is obtained by injecting the Hc beta GRP dsRNA interference system into hyphantria cunea, and the Hc beta GRP dsRNA interference system is applied to the hyphantria cunea. The technical support is provided for the application of the Hc beta GRP RNAi technology. Besides, the dsRNA of the hyphantria cunea Hc beta GRP is combined with the biocontrol bacteria by utilizing an established hyphantria cunea Hc beta GRP RNA interference system, so that the control effect of the biocontrol bacteria can be remarkably improved.

The invention relates to the field of biological detection, in particular to a monoclonal antibody combination for detecting human IL-6 protein and application. The combination comprises monoclonal antibodies 3A10 and 2G1, and amino acid sequences of complementary determining regions of variable regions of light and heavy chains of the monoclonal antibodies 3A10 and 2G1 are respectively shown as SEQ ID NO.1-12. The invention defines a complete variable region sequence and a coding nucleotide sequence of the antibody. The combination specifically recognizes human IL-6 recombinant and natural proteins, and has no cross reaction with IL-11. A double-antibody sandwich ELISA kit constructed based on the combination takes 3A10 as a coating antibody and 2G1 as a labeled antibody, and has high sensitivity and high specificity. The problems that an existing reagent is insufficient in specificity and low in sensitivity are solved, a reliable core raw material is provided for IL-6 standardized detection, and the method is suitable for preparation of a kit, a test strip and an antibody chip.

The invention belongs to the technical field of molecular biology, and particularly relates to a CeNF-YA1 gene, an expression vector and application of the CeNF-YA1 gene in vegetable fat regulation and control. The invention provides the CeNF-YA1 gene for the first time, the nucleotide sequence of the CeNF-YA1 gene is as shown in SEQ ID NO.1, the full length of a coding region of the CeNF-YA1 gene is 792 bp, a series of carriers containing the CeNF-YA1 gene, such as subcellular localization, yeast hybridization and plant overexpression, are constructed for the first time, and meanwhile, the CeNF-YA1 protein is proved to have a transcription activation function, is localized in a cell nucleus and conforms to the basic characteristics of transcription factors. It is found for the first time that overexpression of the CeNF-YA1 gene can significantly improve the grease content of arabidopsis seeds and leaves; therefore, the technical scheme provided by the invention can be used for improving the oil content of the plant seeds and the nutritional tissues, and shows the application prospect in improving the oil content of the seeds and the nutritional tissues.

The invention discloses a screening method of hericium erinaceus functional polypeptide based on artificial intelligence assistance and polypeptide or a polypeptide composition. The method comprises the following steps: (1) constructing an AI auxiliary annotation model; (2) extracting hericium erinaceus crude protein; (3) preparing hericium erinaceus protein enzymatic hydrolysate through composite enzymatic hydrolysis; (4) performing polypeptide identification on the hericium erinaceus protein enzymatic hydrolysate to obtain a polypeptide sequence; and (5) carrying out AI auxiliary annotation and polypeptide screening by using a large language model based on a DeepSeek platform so as to obtain a polypeptide sequence with assumed biological activity. The polypeptide sequence and the polypeptide composition which have remarkable ACE inhibition and oxidation resistance dual functions are successfully obtained by utilizing the method disclosed by the invention. Compared with a traditional experience screening path, the method realizes a high-throughput active peptide development process which is targeted in structure, accurate in prediction and capable of verifying a closed loop.

The invention discloses a novel HIF-2 alpha proteolysis targeting chimera 1 as well as a preparation method and application thereof, the structural formula 1 of the novel HIF-2 alpha proteolysis targeting chimera 1 is shown in the specification, and the obtained novel HIF-2 alpha proteolysis targeting chimera 1 has good proliferation inhibition activity on kidney cancer 786-O cells. The novel HIF-2alpha protein hydrolysis targeting chimera designed by the invention is novel in structure, few in preparation route process steps, easy to obtain raw materials, suitable for industrial production and good in application value.

The invention provides a cell protein degradation platform based on an artificial biological macromolecular aggregate. Specifically, the invention provides a PROTAC functional module based on an interworking nucleic acid skeleton, a PROTAC-aggregate complex (MLO-PROTAC), a kit, application and a preparation method of the PROTAC functional module, the PROTAC-aggregate complex (MLO-PROTAC) and the kit, and also provides a targeted protein degradation method. In a PROTAC platform built by the PROTAC functional module and the PROTAC-aggregate complex, a programmable nucleic acid component is used as a core assembly unit, and the functional module is enriched and spatiotemporal-spatial regulation is performed by using the polypeptide aggregate, so that the delivery efficiency and the cytoplasm exposure degree are remarkably improved while the universality is maintained, and the delivery efficiency and the cytoplasm exposure degree are remarkably improved. Therefore, a more effective target protein degradation way is provided for the field.

The present disclosure provides one or more engineered gene effectors and systems, compositions, and methods of use thereof, wherein the one or more engineered gene effectors can be used to effect regulation of a target gene in a cell (e.g., an endogenous target gene in a cell). The one or more engineered gene effectors can be operatively coupled to a heterologous endonuclease, such as a CRISPR / Cas protein.

The invention discloses a deep learning prediction method fused with multi-modal features, which can accurately identify protein hidden binding sites in a ligand-free (apoo) state. The method comprises the following steps of: firstly, constructing a protein graph by taking residues as nodes and taking C alpha distance less than or equal to 14 as edges, wherein node feature sets comprise amino acid one-hot, secondary structures, atomic attributes, protein language model embedding and BLOSUM62 evolutionary information, and edge features comprise distance and angle similarity; then capturing three-dimensional geometric equivariant features by adopting an equivariant graph neural network (EGNN), and modeling a chemical topological relation by using a graph isomorphic network (GINE) with edge features; eGNN and GINE double-branch feature fusion and global dependence integration are realized through gating cross attention and gating multi-head attention; and finally, inputting the fusion features into a Kolmogorov-Arnold network (KAN) classifier, and predicting whether each residue belongs to a hidden binding site or not. The method can adapt to large-scale conformation change without coordinate alignment, AUC and F1 on a standard data set are remarkably superior to those of an existing method, high robustness and generalization are kept for multi-chain protein and complex conformation, and the method can be widely applied to drug target discovery and structure-driven drug design.

The invention relates to the technical field of biomedicine, in particular to a method for constructing a plasma ctDNA organ distribution characteristic spectrum of advanced colorectal cancer. The method comprises the following steps: collecting a peripheral blood sample at multiple time points, separating plasma by adopting a double-centrifugal method, and extracting circulating tumor DNA (Deoxyribose Nucleic Acid); carrying out whole exome sequencing based on ctDNA to obtain genome variation information and calculating variation allele frequency, and synchronously detecting the expression quantity of immune-related proteins by adopting an Olink proteomics technology; integrating the genome data, the protein expression data and the clinical pathological features, and constructing a multi-dimensional feature data matrix; and taking the organ metastasis condition confirmed by iconography as a supervision label, training a model by applying a machine learning algorithm, screening key prediction factors, constructing a quantitative prediction model, and finally generating a visual organ metastasis tendency prediction map. According to the method, early and accurate prediction of the advanced colorectal cancer organ metastasis tendency is realized through multi-omics data collaborative analysis and machine learning modeling.

The invention relates to the technical field of biology, in particular to a recombinant fusion protein, polynucleotide for coding the recombinant fusion protein, a recombinant expression plasmid containing the polynucleotide, an engineered recombinant host cell and a method for preparing target polypeptide by using the recombinant fusion protein. The recombinant fusion protein comprises tag polypeptide-target polypeptide-(linker 1-linker x-linker 2-target polypeptide) n from N terminal to C terminal, x is the number of linkers, x is 0 or 1, n is a positive integer not less than 1, the tag polypeptide is SEQ ID NO.1 or SEQ ID NO.2, the linker 1 contains a Kex2 protease enzyme cutting site and a carboxypeptidase B enzyme cutting site, and the linker 1 contains a Kex2 protease enzyme cutting site and a carboxypeptidase B enzyme cutting site. And the connecting peptide 2 contains a WELQ protease enzyme cutting site. The recombinant fusion protein disclosed by the invention is expressed in an inclusion body form, the synthesis process is simplified, the target polypeptide can be prepared with high yield and high purity by using the recombinant fusion protein disclosed by the invention, and the production cost can be reduced from multiple dimensions.

96 New PCT-Patent Application based on EP 24 186 635.9 Insempra GmbH Vossius Ref.: AG4141 PCT S3 Abstract The present invention relates to a linear double-stranded deoxyribonucleic acid (dsDNA) molecule comprising one or more Tus protein (Tus) binding site(s) at the 5'-terminus, one or more Lac repressor protein (LacI) binding site(s) at the 3'-terminus, and a segment comprising a DNA sequence of interest (DOI) between said Tus binding site(s) and said LacI binding site(s). The present invention further relates to a non-naturally or naturally occurring RNA molecule as encoded by or transcribable / transcribed from the linear dsDNA molecule of the invention, and to an expression DNA cassette comprising a promoter, an RBS, a GOI encoding a POI, and one or more LacI binding site(s), wherein said expression cassette does not comprise a terminator sequence between the 3´ end of said GOI and said one or more LacI binding site(s). The present invention also relates to a non-naturally or naturally occurring RNA molecule as encoded by or transcribable / transcribed from said expression cassette. The present invention further relates to method of protecting a linear deoxyribonucleic acid (DNA) molecule from exonuclease degradation by adding one or more Tus binding site(s) at the first terminus of the DNA molecule and adding one or more LacI binding site(s) at the other terminus of the DNA molecule. The present invention further relates to a method of synthesizing a protein of interest (POI) in a cell- free protein synthesis (CFPS) reaction mixture by using the (ds)DNA and / or RNA molecules of the invention, and also to a cell-free biological system or CFPS reaction mixture comprising the (ds)DNA, expression cassette and / or RNA molecules of the invention.

The invention relates to a recombinant expression cat interferon-omega gene and a preparation method and application thereof, the nucleotide sequence of the cat interferon-omega gene is as shown in SEQ ID NO.1, and the cat interferon-omega gene is obtained by introducing an Fc fusion fragment to the C terminal and / or N terminal of the natural gene sequence of the cat interferon-omega. XTEN or PAS is introduced to prolong a peptide fragment, and original glycosylation modification sites on a natural sequence are reserved. The method comprises the following steps: cloning a cat interferon-omega gene into an expression vector containing double promoters, further transfecting into a cell, carrying out stable cloning and screening, establishing a high-expression cell strain, and carrying out fermentation culture in a bioreactor. According to the invention, the cat interferon-omega gene is subjected to multiple modification and is efficiently expressed in a CHO-K1GS system, so that the protein yield, the stability and the half-life period are remarkably improved; the obtained fusion protein is high in purity and strong in activity, can obviously enhance immune response and protection effect when being matched with cat vaccines, and is good in safety.

The invention belongs to the technical field of immunochemistry, and particularly relates to an anti-PR recombinant rabbit monoclonal antibody and application thereof.The anti-PR recombinant rabbit monoclonal antibody comprises a heavy chain variable region and a light chain variable region, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO: 4; the amino acid sequence of the light chain variable region is as shown in SEQ ID NO: 5. The invention also relates to a nucleotide sequence for coding the anti-PR recombinant rabbit monoclonal antibody, a recombinant plasmid or an expression vector, a preparation method, application of the anti-PR recombinant rabbit monoclonal antibody in a PR protein detection method or device, and the like. The PR recombinant rabbit monoclonal antibody disclosed by the invention has the characteristics of good specificity, strong positive signal and the like, so that scoring is easier in IHC staining, and cancer detection and distinguishing are more accurate.

According to the screening method for the potential protein biomarkers and the drug targets of the gastric cancer, Mendel randomization analysis in a proteome range is adopted, the genetic causal relationship between circulating plasma protein and the risk of the gastric cancer is evaluated, and finally the remarkably related protein is identified. According to the screening method of the potential protein biomarker and the drug target of the gastric cancer, provided by the invention, the potential association between circulating plasma protein and the gastric cancer is systematically revealed by integrating Mendel randomization, single-cell RNA sequencing analysis, space transcriptome analysis, virtual drug screening, molecular docking, molecular dynamics simulation and other methods.

The invention provides a method for analyzing interaction between procambarus clarkia arginine kinase and shark source nano antibody. The method comprises the following steps: performing three-dimensional structure prediction on a VNAR sequence, and screening a high-confidence VNAR model by using a Laplace map; docking an amino acid sequence corresponding to the VNAR model with an arginine kinase sequence to obtain an optimal compound model, and analyzing an interaction site of an arginine kinase epitope region and a nanometer antibody complementary determining region CDR3; performing molecular dynamics simulation on the compound model, calculating conformational change indexes and binding free energy through energy optimization, system balance and extended simulation sampling, and outputting a binding stability sequence of the nano antibody and arginine kinase; the method comprises the following steps: screening out a high-stability nano antibody, pre-incubating a fusion protein of the high-stability nano antibody and immobilized arginine kinase to form a compound, adding serum of an allergic patient for competitive binding, quantifying the binding activity of residual IgE through an immunodetection technology, and verifying the inhibition effect of the shark source nano antibody on the sensitization effect of arginine kinase.

The invention belongs to the technical field of bioengineering, and particularly relates to a nucleic acid aptamer specifically bound with MMLV, and the nucleotide sequence of the nucleic acid aptamer is as shown in SEQ ID NO.1 or SEQ ID NO.2; the nucleic acid aptamer capable of being specifically bound with MMLV is obtained through screening on the basis of the SELEX technology, has high affinity for MMLV protein, can be applied to MMLV protein enrichment reagents, MMLV protein separation reagents, MMLV protein detection reagents, test paper and biosensors, and facilitates identification and activity research of the MMLV protein.

The invention discloses a drug delivery system based on branched chain nucleic acid as well as a preparation method and application of the drug delivery system. The drug delivery system comprises a multivalent nucleic acid framework, a nucleic acid-small molecule coupling drug and a nucleic acid-polypeptide coupling drug, a nucleic acid nanostructure is formed through base complementary pairing assembly, and the nucleic acid-small molecule coupling drug comprises first nucleic acid and an E3 ubiquitin ligase ligand coupled with the first nucleic acid; the nucleic acid-polypeptide coupling drug comprises a second nucleic acid and a cell penetrating peptide coupled with the second nucleic acid. The drug delivery system disclosed by the invention can respond to a tumor microenvironment, so that cell penetrating peptides are activated, tumor penetrating and cytoplasm delivery capacities are enhanced, the aim of efficiently degrading tumor-related target proteins is fulfilled by combining a multivalent effect, and a remarkable tumor treatment effect is achieved; in addition, the preparation method is simple and easy to implement, has universality and high production efficiency, and is expected to be applied to treatment of various tumors.

Provided herein is a recombinant polyclonal protein library (RPP) generated, at least in part, by an in silica method. Also provided are methods of using the RPP.

The invention relates to the technical field of nuclide probes, and discloses a targeted PARP nuclide probe and a preparation method and application thereof, and the targeted PARP nuclide probe comprises a radionuclide labeled compound as shown in formula I; the targeted PARP nuclide probe provided by the invention can be used as a diagnosis and treatment reagent to be applied to tumors with high PARP protein expression in human or animal bodies, and is especially suitable for tumor imaging and radionuclide treatment; animal experiments show that the nuclide probe has a high tumor / muscle uptake ratio and shows good application potential. Formula I.

The invention belongs to the technical field of biological detection, and relates to an antibody composition aiming at human pS129-alpha-Syn protein detection and application thereof, and the antibody composition comprises a targeted pS129-alpha-Syn protein phosphorylation antibody and a targeted human alpha-synuclein N-terminal antibody. Meanwhile, based on the antibody composition for detecting the human pS129-alpha-Syn protein, the invention further provides a kit for early diagnosis of the Parkinson's disease. The invention provides an antibody composition aiming at human pS129-alpha-Syn protein detection and application of the antibody composition. The antibody composition is higher in detection specificity and sensitivity.

The invention discloses a high-flux and rapid chromatin immunoprecipitation sequencing method based on a HiBiT tag and a Tn5 enzyme, and belongs to the technical field of biology. According to the method, the high affinity characteristic of a HiBiT tag system is combined with a Tn5 enzyme in-situ library building technology, firstly, a DNA binding protein recombinant expression strain containing a HiBiT tag is constructed and subjected to induced expression, after formaldehyde crosslinking and cell lysis, an Anti-HiBiT antibody is used for rapid immunoprecipitation, and a Tn5 enzyme library is constructed; tn5 transposase is directly loaded on the magnetic beads combined with the protein and DNA fragment compound to complete fragmentation and linker connection, so that the construction of a next-generation sequencing library is quickly carried out, and the total consumed time from immunoprecipitation to the completion of library construction is less than or equal to 5 hours. Meanwhile, automatic treatment is realized through a micro experiment board (the reaction system is less than or equal to 200 microliters) and a liquid workstation, the experiment cost and the sample dosage are reduced, 48 transcription factors and 48 control samples can be synchronously treated, the efficiency is greatly improved, and an efficient tool is provided for microbial transcription regulation and control research.

The present disclosure provides evolved and engineered reverse transcriptase variants and Cas9 variants with improved properties (e.g., improved editing efficiency when used in a guided editor context). The disclosure also provides fusion proteins comprising the reverse transcriptase variants and Cas9 variants described herein, including, for example, a guided editor. The disclosure also provides polynucleotides encoding the reverse transcriptase variants, Cas9 variants, and guide editors provided herein, as well as vectors comprising such polynucleotides. The disclosure also provides pharmaceutical compositions and cells comprising the reverse transcriptase variants, Cas9 variants, and a guided editor described herein. The present disclosure also provides methods and uses relating to the reverse transcriptase variants, Cas9 variants, and guide editors described herein.

The invention provides recombinant III-type collagen and application thereof, and relates to the technical field of genetic engineering. According to the invention, the yield of the collagen is improved by optimizing the nucleotide sequence of the target gene and optimizing the culture conditions of pichia pastoris, so that the collagen is efficiently expressed in engineering bacteria. The recombinant engineering bacterium shows strong potential in the aspect of improving the yield of protein with high economic value, and is suitable for large-scale industrial production. The recombinant III-type collagen is high in expression quantity, simple in preparation process and suitable for preparation of biological materials for medical cosmetology, wound repair and the like, and has a wide application prospect.

The invention provides a method and a system for predicting early gastric cancer prognosis by a circulating marker, and relates to the technical field of auxiliary diagnosis. The method comprises the following steps: performing multi-omics detection on a blood sample based on a preset sampling time sequence to obtain a multi-dimensional time sequence characteristic data set containing three groups of heterogeneous data of circulating tumor DNA, exosomes and protein markers; calculating a change slope and a fluctuation variance of the heterogeneous data in adjacent time sequence intervals, constructing a dynamic variation feature matrix in combination with a standard attenuation weighting factor, and deeply mining spatial cross-correlation and sequence dependence features of the matrix to generate a multi-modal fusion feature fingerprint; and performing regression operation on the feature fingerprints by using an integrated learning stack model to obtain a dynamic prognosis risk score, and further retrieving a risk hierarchical mapping table to generate a prognosis evaluation result containing a survival curve. According to the method, multi-modal heterogeneous data can be effectively fused, the biological dynamic characteristics in the tumor postoperative recovery phase are captured, and the accuracy and timeliness of early gastric cancer prognosis prediction are remarkably improved.

Aspects of the disclosure relate to recombinant gene editing complexes comprising a recombinant gene editing protein and guide RNA (gRNA) that specifically hybridizes to a region of a C90RF72 gene (e.g., a region flanking a G4C2 repeat or within a exonic region of the gene).

The invention relates to the field of molecular biology, and discloses a nucleic acid releasing agent for isothermal amplification and a use method of the nucleic acid releasing agent. Comprising the following steps: step 1, preparing a polyoxypropylene polyoxyethylene copolymer diluent, a defoaming agent SE-15 diluent, an ethyl phenyl polyethylene glycol NP-40 diluent, a sodium polyethylene sulfonate diluent and a Proclin300 diluent in sequence through RNA enzyme-free water; and 2, sequentially preparing an ethylenediamine tetraacetic acid disodium salt mother solution, a sodium dodecyl sulfate mother solution and a glycine mother solution through RNA enzyme-free water. Sodium polyethylene sulfonate can be specifically combined with protein amplification inhibitors in a sample to remove mucoprotein, hemoglobin, polysaccharide and other inhibitors in the swab sample, and disodium ethylene diamine tetraacetate can chelate metal ions to reduce the influence of nuclease on target nucleic acid.

The invention provides a drug target prediction method based on cross-modal attention and uncertainty evaluation, and belongs to the technical field of drug target prediction. In order to solve the technical problems that the existing drug target prediction lacks quantitative evaluation on the reliability of a prediction result and a nonlinear interaction relationship between a drug and a target is difficult to establish, the method comprises the following steps: collecting data, and fusing graph structure features and sequence features of extracted drug molecules to obtain a final code of the drug molecules; extracting amino acid sequence characteristics of the target protein, and constructing protein sequence characteristic expression; inputting the drug molecular features and the protein sequence features into a cross-modal attention module, and aligning and fusing the drug features and the protein features by using a bidirectional cross attention mechanism to obtain drug-target combined feature representation; introducing an uncertainty quantification mechanism, and outputting uncertainty estimation of a drug-target interaction prediction label and a prediction result; the method is used for predicting drug target interaction.